Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy

Journal of Nuclear Medicine

Volumn 49, Issue 12, 2008, Pages 2006-2011

  Phil, Hyu Lee ^a   Seok, Woo Yong ^b   An, Young Sil ^c  

^a Yonsei University College of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

Author keywords

Cerebral metabolism; Cholinesterase inhibitor; Neurology; Parkinson disease dementia; PET

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; CHOLINESTERASE INHIBITOR; DONEPEZIL; ENTACAPONE; FLUORODEOXYGLUCOSE F 18; GALANTAMINE; GLUCOSE; LEVODOPA; ROPINIROLE;

AGED; ARTICLE; BRAIN METABOLISM; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; COVARIANCE; DEMENTIA; DRUG DOSE INCREASE; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NERVE CELL; ORBITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL PARAMETERS;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BRAIN; CHOLINESTERASE INHIBITORS; DEMENTIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; PARKINSON DISEASE; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 57149086099     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.054668     Document Type: Article

References (40)

1. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology. 2001;56:730-736.
2. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord. 2005;20:1255-1263.
3. Caballol N, Marti MJ, Tolosa E. Cognitive dysfunction and dementia in Parkinson disease. Mov Disord. 2007;22(suppl 17):S358-S366.
4. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22:1689-1707.
5. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol. 2003;2:229-237.
6. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68:812-819.
7. Mattila PM, Röyttä M, Lönnberg P, Marjamäki P, Helenius H, Rinne JO. Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol (Berl). 2001;102:160-166.
8. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1985;48:413-421.
9. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol. 2006;253:242-247.
10. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351:2509-2518.
11. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72:708-712.
12. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003;18:937-941.
13. Ceravolo R, Volterrani D, Frosini D, et al. Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. J Neural Transm. 2006;113:1787-1790.
14. Ishii K, Hosaka K, Mori T, Mori E. Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies. Ann Nucl Med. 2004;18:447-451.
15. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, DSM-IV. 4th ed. Washington DC: American Psychiatric Association; 1994.
17. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863-1872.
18. 123I-MIBG scintigraphy in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry. 2006;77:372-374.
19. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273-289.
20. Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology. 2000;54:407-411.
21. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003;60:1745-1748.
22. 18FDG-PET in Alzheimer's disease: a double-blind cross-over trial. Psychopharmacology (Berl). 2006;187:86-94.
23. Stefanova E, Wall A, Almkvist O, et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J Neural Transm. 2006;113:205-218.
24. Potkin SG, Anand R, Fleming K, et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol. 2001;4:223-230.
25. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;65:1716-1722.
26. Firbank MJ, Colloby SJ, Burn DJ, McKeith IG, O'Brien JT. Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage. 2003;20:1309-1319.
27. Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol. 2007;14:1357-1362.
28. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. J Alzheimers Dis. 2007;11:509-519.
29. Herholz K, Bauer B, Wienhard K, et al. In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism. J Neural Transm. 2000;107:1457-1468.
30. Mori T, Ikeda M, Fukuhara R, Nestor PJ, Tanabe H. Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology. 2006;66:935-937.
31. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718-1725.
32. 11C]PIB binding in Parkinson's disease dementia. Neuroimage. 2008;39:1027-1033.
33. Ceravolo R, Volterrani D, Tognoni G, et al. Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease. Clin Neuropharmacol. 2004;27:166-170.
34. Vennerica A, Shanks MF, Staff RT, et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport. 2002;13:83-87.
35. 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology. 2006;66:1850-1854.
36. Halgren E, Dale AM, Sereno MI, Tootell RB, Marinkovic K, Rosen BR. Location of human face-selective cortex with respect to retinotopic areas. Hum Brain Mapp. 1999;7:29-37.
37. Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology. 2005;65:1708-1715.
38. Mosimann UP, Mather G, Wesnes KA, O'Brien JT, Burn DJ, McKeith IG. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology. 2004;63:2091-2096.
39. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord. 2006;21:1899-1907.
40. Bentley P, Driver J, Dolan RJ. Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health. Brain. 2008;131:409-424.